Professional support
Many organisations, medical practitioners, charities, and MPs support the use of Evusheld/Sipavibart for immunocompromised patients.
More than 100 clinicians also called on the Government in August of 2022 to make a preventative treatment for COVID-19 available in the UK to the approximate 1.8M clinically vulnerable people who may benefit from it.
The prophylactic monoclonal antibody treatment Evusheld was approved for use in March 2022, but it was not made available on the NHS, when it was being used in 28 countries, including the United States, France and Israel.
The All Party Parliamentary Group for Vulnerable Groups to Pandemic had asked Dr. Lennard Lee, academic lecturer and medical oncologist at Oxford University, to carry out a clinical consultation to ask clinicians how to help the people still at risk who do not have protection from vaccination.
125 clinicians responded across 17 medical specialities to the largest-known consultation in the UK, if not the world, about this new step of the pandemic response.
The consultation statement sets out the clinical benefits of making monoclonal prophylactic antibody therapies available – detailing how it helps from an individual level, to prevent infections, hospitalisation, and deaths. It also would help improve mental health and give immunocompromised people the confidence to reduce shielding. The statement also suggested it would help the broader health care system by reducing demand on the primary care, emergency services, and intensive care if there were a reduction in serious infections in immunocompromised people.
Read the National Clinical Expert Statement.
We have also worked with Dr. Luca Bernardi of Liverpool University and Dr. Jo Daniels of Bath University, in conjunction with the APPG VGP in the production of the Forsaken but Engaged. An inquiry into the psychological aspects of COVID 19, mental health, and political engagement survey, which was unique in highlighting how both the mental health and political engagement of the immunocompromised are impacted and launched this in a widely attended debate in Parliament in December 2023.
Charity support